Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Causal Relationships between Lipid-Lowering Drug Target and Aortic Disease and Calcific Aortic Valve Stenosis: A Two-Sample Mendelian Randomization

Open access
Yang, Liang, Xu, Mingyuan, Gao, Xixi, Liu, Jingwen, Zhang, Dingkai, Zhang, Zhaohua, Ye, Zhidong, Wen, Jianyan, Liu, Peng · 2024 · Reviews in Cardiovascular Medicine

Abstract

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), cholesteryl ester transfer protein (CETP) and apolipoprotein C3 (APOC3) are pivotal regulators of lipid metabolism, with licensed drugs targeting these genes. The use of lipid-lowering therapy via the inhibition of these genes has demonstrated a reduction in the risk of cardiovascular disease. However, concerns persist regarding their potential long-term impact on aortic diseases and calcific aortic valve disease (CAVS). This study aims to investigate causal relationships between genetic variants resembling these genes and aortic disease, as well as calcific aortic valve disease using Mendelian randomization (MR). Methods: We conducted drug-target Mendelian randomization employing summary-level statistics of low-density lipoprotein cholesterol (LDL-C) to proxy the loss-of-function of PCSK9, HMGCR, CETP and APOC3. Subsequently, we investigated the association between drug-target genetic variants and calcific aortic valve stenosis and aortic diseases, including thoracic aortic aneurysm (TAA), abdominal aortic aneurysm (AAA), and aortic dissection (AD). Results: The genetically constructed variants mimicking lower LDL-C levels were associated with a decreased risk of coronary artery disease, validating their reliability. Notably, HMGCR inhibition exhibited a robust protective effect against TAA (odds ratio (OR): 0.556, 95% CI: 0.372–0.831, p = 0.004), AAA (OR: 0.202, 95% CI: 0.107–0.315, p = 4.84 × 10-15), and AD (OR: 0.217, 95% CI: 0.098–0.480, p = 0.0002). Similarly, PCSK9, CETP and APOC3 inhibition proxies reduced the risk of AAA (OR: 0.595, 95% CI: 0.485–0.730, p = 6.75 × 10-7, OR: 0.127, 95% CI: 0.066–0.243, p = 4.42 × 10-10, and OR: 0.387, 95% CI: 0.182–0.824, p = 0.014, respectively) while showing a neutral impact on TAA and AD. Inhibition of HMGCR, PCSK9, and APOC3 showed promising potential in preventing CAVS with odds ratios of 0.554 (OR: 0.554, 95% CI: 0.433–0.707, p = 2.27 × 10-6), 0.717 (95% CI: 0.635–0.810, p = 9.28 × 10-8), and 0.540 (95% CI: 0.351–0.829, p = 0.005), respectively. However, CETP inhibition did not demonstrate any significant benefits in preventing CAVS (95% CI: 0.704–1.544, p = 0.836). The consistency of these findings across various Mendelian randomization methods, accounting for different assumptions concerning genetic pleiotropy, enhances the causal inference. Conclusions: Our MR analysis reveals that genetic variants resembling statin administration are associated with a reduced risk of AAA, TAA, AD and CAVS. HMGCR, PCSK9 and APOC3 inhibitors but not CETP inhibitors have positive benefits of reduced CAVS. Notably, PCSK9, CETP and APOC3 inhibitors exhibit a protective impact, primarily against AAA, with no discernible benefits extending to TAA or AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.31083/j.rcm2508292

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Flowchart of the study. APOC3, apolipoprotein C3; CETP, cholesteryl ester transfer protein; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; LDL-C, low-density lipoprotein cholesterol; MR, Mendelian randomization; SNPs, single-nucleotide polymorphisms; PCSK9, proprotein convertase subtilisin/kexin type 9.
Fig. 1. Flowchart of the study. APOC3, apolipoprotein C3; CETP, cholesteryl ester transfer protein; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; LDL-C, low-density lipoprotein cholesterol; MR, Mendelian randomization; SNPs, single-nucleotide polymorphisms; PCSK9, proprotein convertase subtilisin/kexin type 9.CC BY · PubMed Central
Fig. 2. Association of lipid drug targets with aortic disease and calcific aortic valve stenosis using the inverse variance weighted (IVW) method. AAA, abdominal aortic aneurysm; AD, aortic dissection; APOC3, apolipoprotein C3, CETP, cholesteryl ester transfer protein; CAVS, calcific aortic valve stenosis; CI, confidence interval; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; LDL-C, low-density lipoprotein cholesterol; SNPs, single-nucleotide polymorphisms; PCSK9, proprotein convertase subtilisin/kexin type 9; TAA, thoracic aortic aneurysm.
Fig. 2. Association of lipid drug targets with aortic disease and calcific aortic valve stenosis using the inverse variance weighted (IVW) method. AAA, abdominal aortic aneurysm; AD, aortic dissection; APOC3, apolipoprotein C3, CETP, cholesteryl ester transfer protein; CAVS, calcific aortic valve stenosis; CI, confidence interval; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; LDL-C, low-density lipoprotein cholesterol; SNPs, single-nucleotide polymorphisms; PCSK9, proprotein convertase subtilisin/kexin type 9; TAA, thoracic aortic aneurysm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 6

Metadata

Authors
Yang, L., Xu, M., Gao, X., Liu, J., Zhang, D., Zhang, Z., Ye, Z., Wen, J., & Liu, P.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Peking University (CN)
Corresponding author
  • Wen, Jianyan
  • Liu, Peng
Venue
Reviews in Cardiovascular Medicine
Publisher
IMR Press
Published
2024-08-19
Volume
25
Issue
8
Pages
292-292
ISSN
  • 1530-6550 (ISSN-L)
  • 2153-8174
OpenAlex
W4402012467
Cited by
6
References
59
Citations by year
2026: 3 · 2025: 3
FWCI
1.59
Type
journal article
Language
en
Open access
Locations
  • Reviews in Cardiovascular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (82270443, 82170066, 81670275, 81670443)
  • National High Level Hospital Clinical Research Funding (2022-NHLHCRF-ZSYX-01)
  • International S&T cooperation program (2013DFA31900)
  • Major New Drug Creation Special Project, Ministry of Science and Technology of the People’s Republic of China (2020ZX09201-012)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords
calcific aortic stenosis, aortic disease, thoracic aortic aneurysm, abdominal aortic aneurysm, aortic dissection, PCSK9, HMGCR, cholesteryl ester transfer protein, apolipoprotein C-III, lipid-lowering drugs, LDL cholesterol, coronary artery disease, causal relationship, statins, ezetimibe

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Causal Relationships between Lipid-Lowering Drug Target and Aortic Disease and Calcific Aortic Valve Stenosis: A Two-Sample Mendelian Randomization. https://app.cochat.ai/papers/10.31083/j.rcm2508292
The paper
Yang, L., Xu, M., Gao, X., Liu, J., Zhang, D., Zhang, Z., Ye, Z., Wen, J., & Liu, P. (2024). Causal Relationships between Lipid-Lowering Drug Target and Aortic Disease and Calcific Aortic Valve Stenosis: A Two-Sample Mendelian Randomization. Reviews in Cardiovascular Medicine. https://doi.org/10.31083/j.rcm2508292

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.